Alpha 2.0
Login Register
» Authors » Quentin Van Thillo

Quentin Van Thillo

Explore the profile of Quentin Van Thillo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 49
Followers 0
Related Specialties
Hematology
Pulmonary Medicine
Biology
Top 10 Co-Authors
Peter Verhamme
Iwein Gyselinck
Ann Belmans
Jan Cools
Laurens Liesenborghs
Sofie Demeyer
Matthias M Engelen
Sarah Provost
Albrecht Betrains
Olga Gielen
Published In
Nat Commun
Blood
J Thromb Haemost
Eur Respir J
Res Pract Thromb Haemost
Affiliations
Soon will be listed here.
Recent Articles
1.
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia
Lauwereins L, Van Thillo Q, Demeyer S, Mentens N, Provost S, Jacobs K, et al.
Leukemia . 2025 Jan; 39(3):568-576. PMID: 39838044
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological disease originating from the malignant transformation of T-cell progenitors, caused by the accumulation of genetic aberrations. One-fifth of T-ALL patients are...
2.
Multigene panel for thrombophilia testing in venous thromboembolism
Verstraete A, De Vera M, Van Laer C, Van Thillo Q, Baert S, Kint C, et al.
J Thromb Haemost . 2025 Jan; PMID: 39800257
Background: Conventional tests for inherited thrombophilia focus on the 5 most-established inherited thrombophilias; ie deficiencies in antithrombin, protein C, and protein S, and the factor V Leiden and prothrombin G20210A...
3.
Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion
Van Thillo Q, Dewaele B, De Bie J, Michaux L, Devos T, Vandenberghe P
Br J Haematol . 2023 May; 202(1):e7-e10. PMID: 37129059
No abstract available.
4.
Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study
Engelen M, Van Thillo Q, Betrains A, Gyselinck I, Martens C, Spalart V, et al.
Res Pract Thromb Haemost . 2022 Nov; 6(7):e12826. PMID: 36324831
Background: Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in...
5.
Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma
Vanden Bempt M, Debackere K, Demeyer S, Van Thillo Q, Meeuws N, Prieto C, et al.
Blood . 2022 Aug; 140(23):2463-2476. PMID: 35960849
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological cancers arising from the malignant transformation of mature T cells. In a cohort of 28 PTCL cases, we identified recurrent...
6.
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Gyselinck I, Liesenborghs L, Belmans A, Engelen M, Betrains A, Van Thillo Q, et al.
ERJ Open Res . 2022 Mar; 8(1). PMID: 35233389
Background And Objectives: Azithromycin was rapidly adopted as a repurposed drug to treat coronavirus disease 2019 (COVID-19) early in the pandemic. We aimed to evaluate its efficacy in patients hospitalised...
7.
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, et al.
Eur Respir J . 2021 Aug; 59(2). PMID: 34446469
Background: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at...
8.
Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia
Van Thillo Q, De Bie J, Seneviratne J, Demeyer S, Omari S, Balachandran A, et al.
Nat Commun . 2021 Jul; 12(1):4164. PMID: 34230493
Spi-1 Proto-Oncogene (SPI1) fusion genes are recurrently found in T-cell acute lymphoblastic leukemia (T-ALL) cases but are insufficient to drive leukemogenesis. Here we show that SPI1 fusions in combination with...